A research success by diabetes specialist Novo Nordisk dealt a heavy blow to the shares of dialysis providers on Wednesday. Shares of Fresenius Medical Care slumped by almost a quarter at their peak.
In his latest research note, analyst David Adlington confirms his positive recommendation. The broker JP Morgan is keeping its Buy rating. The target price has been revised downwards and is now set at.
U.S. bank JPMorgan cut its price target for Gerresheimer to 139.60 euros from 148.50 euros, but kept its rating at Overweight. The specialty packaging maker s management had tempered expectations for.